Compass Pathways Launches U.S. HCP Education Campaign Amid Psych Congress 2026 — Compass Pathfinder Limited

Event summary

Compass Pathways will debut 'Change the Tune in TRD,' a U.S. HCP education campaign focused on treatment-resistant depression (TRD), at Psych Congress 2026 on September 15.
The company will present new health economics and outcomes research (HEOR) data on TRD, including real-world healthcare costs and resource utilization.
Encore presentations from the COMP360 psilocybin clinical development program will cover demographic characteristics, efficacy, and safety data from Phase 3 trials.
Psych Congress 2026 takes place in New Orleans, LA, from September 14-19.

The big picture

Compass Pathways' participation at Psych Congress 2026 underscores its strategic focus on advancing psilocybin-based treatments for TRD. The company's educational campaign and HEOR data presentations aim to address the significant unmet need in mental health care, particularly as TRD affects approximately 4 million patients in the U.S. The broader industry trend toward psychedelic-assisted therapies highlights the potential for rapid-onset, durable treatments with infrequent dosing, positioning Compass Pathways at the forefront of this emerging field.

What we're watching

Regulatory Pathway: Whether Compass Pathways can secure FDA approval for COMP360 psilocybin on an accelerated basis, given the Breakthrough Therapy designation.
Market Adoption: The pace at which healthcare providers adopt psilocybin-based treatments for TRD following educational campaigns and data presentations.
Commercialization Readiness: How Compass Pathways prepares for commercialization if regulatory approval is obtained, including coverage and reimbursement strategies.